Lilly’s ‘triple G’ agonist triumphs in Phase III trial, but AEs unnerve analysts
While retatrutide may have the best weight loss efficacy to date, analysts hold concerns about its tolerability profile compared with best-seller, tirzepatide.
22 May 2026
22 May 2026
While retatrutide may have the best weight loss efficacy to date, analysts hold concerns about its tolerability profile compared with best-seller, tirzepatide.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.